P. Johansen

The Cost-Effectiveness Of Canagliflozin Verse Liraglutide In Patients With Type 2 Diabetes (T2dm) Failing To Achieve Glycaemic Control On Metformin Monotherapy In Ireland

were sourced from the literature. Both costs and outcomes were discounted at 5%. Results: Incremental costs, QALYs and ICERs for canagliflozin vs. sitagliptin were € 1,360, 0.059 QALYs and € 23,118 per QALY, respectively, in dual therapy; € 108, 0.093 QALYs and € 1,172 per QALY, respectively, in triple therapy; and € 550, 0.068 QALYs and € 8,047 per QALY, respectively, in add-on to insulin. In all three scenarios, canagliflozin was cost-effective using the acceptable willingness-to-pay threshold in Ireland. Sensitivity analyses suggest that these results are robust. ConClusions: These simulations suggest that the use of canagliflozin in patients in need of additional glycaemic control in dual, triple and add-on to insulin lines of therapy is a more efficient use of health care funds than the use of sitagliptin in the Irish setting.